Introduction {#s1}
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and the second leading cause of cancer-related death in Taiwan. In addition to common risk factors such as hepatitis B and hepatitis C, recent studies have shown that gene mutations may influence the inflammation mechanism that contributes to cell differentiation, proliferation, and apoptosis and connects several diseases and cancers [@pone.0089930-Zhuang1]--[@pone.0089930-Huang1]. Genotypes and mutations on hepatitis were associated to HCC, such as genotype C HBV increased the risk of cirrhosis and HCC, and genotype B HBV is associated with HCC in the patients under 50 years old [@pone.0089930-Yin1]. Also, viral mutations on the promoter region and preS region are significantly increased the risk of HCC. The variances of genotype, mutations and viral load can be used as a prediction of HCC [@pone.0089930-Zhang1].

Micro RNAs (miRNAs) are small RNA fragments typically composed of only 20--22 nucleotides. MiRNAs can target specific mRNAs and negatively regulate their translational efficiency and stability to control the downstream cellular process including proliferation, differentiation, and survival [@pone.0089930-Bartel1], [@pone.0089930-Ambros1]. According to the various functions of miRNAs, some studies have associated miRNAs with the immune system and inflammatory diseases [@pone.0089930-Feng1], [@pone.0089930-Perry1]. Moreover, based on the functions that regulate cell differentiation, proliferation, and survival, several studies have identified a relationship between miRNAs and cancer [@pone.0089930-deRinaldis1]--[@pone.0089930-Xu1].

Single-nucleotide polymorphisms (SNPs) are variations of DNA sequences that occur when nucleotides (A, T, C, or G) are changed by at least 1% in certain populations. Previous epidemiologic studies have shown that genetic variations in miRNAs are associated with various diseases and cancers [@pone.0089930-Linhares1]--[@pone.0089930-Zhong1]. Several studies have provided evidence that SNPs in miRNAs may be related to patients' clinical prognosis [@pone.0089930-deLarrea1]--[@pone.0089930-Teo1], and high expression of miRNA causes superior survival. According to the various functions, low expression of miRNA can yield opposite results [@pone.0089930-Liu2], [@pone.0089930-Rani1].

Based on the aforementioned reasons, we adopted a case-control research design and 4 pre-miRNA SNPs associated with cancer, namely, has-mir-146a (rs2910164), has-mir-149 (rs2292832), has-mir-196a2 (rs11614913), and has-mir-499 (rs3746444) [@pone.0089930-Jeon1]--[@pone.0089930-Liu3]. We also considered the environmental risk factors for hepatocellular carcinoma such as smoking status and alcohol consumption. Furthermore, the clinical stage and laboratory status were combined to define the relationship between SNPs and patient susceptibility to hepatocellular carcinoma.

Materials and Methods {#s2}
=====================

Subjects Selection {#s2a}
------------------

This study recruited 188 HCC patients at the Chung Shan Medical University Hospital, Taiwan. The diagnosis of HCC was made according to the criteria specified in the national guidelines for HCC. During the same study period, 337 ethnic group-matched individuals were enrolled as the controls that entered the physical examination at the same hospital. These control groups had neither self-reported history of cancer of any sites. As for cases and controls, exposure information, including tobacco use (smoker vs. non-smoker) and alcohol consumption (current heavy drinker, defined by CDC as consuming an average of more than 2 drinks per day vs. not current heavy drinker), were all obtained from questionnaires. We also collected the laboratory status such as α-Fetoprotein, AST, ALT and AST/ALT ratio for the further analysis. Before commencing the study, approval was obtained from the Institutional Review Board of Chung Shan Medical University Hospital and informed written consent was obtained from each individual.

DNA Extraction {#s2b}
--------------

We collected the whole blood samples from healthy controls and hepatocellular carcinoma patients with tubes containing EDTA, after centrifuged and stored at −20°C. The venous blood from each subject was drawn into Vacutainer tubes containing EDTA and stored at 4°C. Genomic DNA was extracted by QIAamp DNA blood mini kits (Qiagen, Valencia, USA) according to the manufacture's instructions and the DNA was dissolved in TE buffer \[10 mM Tris (PH 7.8), 1 mM EDTA\] and then quantitated by a measurement of OD260. Final DNA preparation was stored at −20°C and used as templates for the following experiments [@pone.0089930-Yu1].

Polymerase Chain Reaction-restriction Fragment Length Polymorphism (PCR-RFLP) {#s2c}
-----------------------------------------------------------------------------

The SNP of miRNAs gene rs2910164, rs11614913, and rs3746444 polymorphisms were determined by PCR-RFLP assay [@pone.0089930-Chu1]. Amplify The has-mir-146a rs2910164 genotype were used the forward primer 5′- CATGGGTTGTGTCAGTGTCAGAGCT-3′ and the reverse primer 5′- TGCCTTC TGTCTCCAGTCTTCCAA-3′; the has-mir-196a2 rs 11614913 genotype were used forward primer 5′- CCCCTTCCCTTCTCCTCCAGATA-3′ and reverse primer 5′- CGAAAACCGACTGATGTAACTCCG-3′ and the has-mir-499 rs3746444 genotype were used forward primer 5′-CAAAGTCTTCACTTCCCTGCCA-3′ and reverse primer 5′-GATGTTTAACTCCTCTCCACGTGATC-3′. PCR was performed with total 10 µl volume with 100 ng DNA template, 1.0 µl of 10X PCR buffer (Invitrogen, Carslbad, CA, USA), 0.25 U of Taq DNA polymerase (Invitrogen), 0.2 mM dNTPs (Promega, Madison, WI, USA) and 200 nM of each primer (MDBio Inc. Taipei, Taiwan). The PCR conditions were 5 min at 94°C followed by 35 cycles of 30 sec at 94°C, 30 sec at 58°C for hsa-mir-146a rs2910164, 30 sec at 63°C for has-mir-196a2 rs11614913, and 30 sec at 67°C for hsa-mir-499 rs3746444, and 1 min at 72°C, and final step at 72°C for 10 min to allow a complete extension of all PCR fragments. PCR products of hsa-mir-146a rs2910164 gene polymorphism were subjected *SacI* to enzymatic digestion by incubation for 4 hr at 37°C and then submitted to electrophoresis in 2% agarose gels; *MspI* for hsa-mir-196a2 rs2910164 and *BclI* for hsa-mir-499 rs3746444.

Real-time PCR {#s2d}
-------------

MiRNA149 rs2292832 gene polymorphism was assessed using an ABI StepOne™ Real-Time PCR System (Applied Biosystems), SDS v3.0 software (Applied Biosystems), and the TaqMan assay. The final volume for each reaction mixture was 5 µL, containing 2.5 µL TaqMan Genotyping Master Mix, 0.125 µL TaqMan probes mix, and 10 ng genomic DNA. The reaction conditions included an initial denaturation step at 95°C for 10 min followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. For each assay, appropriate controls (nontemplate and known genotype) were included in each typing run to monitor reagent contamination and as a quality control. To validate results from real-time PCR, around 5% of assays were repeated and several cases of each genotype were confirmed by the DNA sequence analysis [@pone.0089930-Wei1].

Statistical Analysis {#s2e}
--------------------

Hardy--Weinberg equilibrium was assessed using a chi-square goodness-of-fit test for biallelic markers. The distributions of demographic characteristics and genotype frequencies between cases and controls in different genotypes were analyzed by Chi-square test, and Fisher's exact test were using at small sample size was present in some categories of variables. The Student's T-test was using to estimate laboratory status between the two groups. The odds ratios (ORs) and their 95% confidence intervals (CIs) of the association between genotype frequencies and hepatocellular carcinoma were estimated by multiple logistic regression models, also controlling for covariates. The *p* value of less than 0.05 was considered significant. The data were analyzed on SPSS 12.0 statistical software.

Results {#s3}
=======

Study Population {#s3a}
----------------

The demographic characteristics of the 2 groups, including age, sex, smoking status, and alcohol consumption, are shown in [Table 1](#pone-0089930-t001){ref-type="table"}. A significant difference in smoking status was observed between the 2 groups (*p = *0.03).

10.1371/journal.pone.0089930.t001

###### Demographic characteristics of controls and patients with hepatocellular carcinoma.

![](pone.0089930.t001){#pone-0089930-t001-1}

  Variable                                               Control        Case          Total                     *p* value
  --------------------------------------------------- ------------- ------------- ------------- ------------------------------------------
  Age                                                                                           
  \<45                                                  24 (7.12)     10 (5.05)     34 (6.48)                      0.06
  45--59                                               210 (40.06)   58 (30.85)    193 (36.76)  
  \>60                                                 178 (52.82)   120 (63.83)   298 (56.76)  
  Gender                                                                                        
  Women                                                85 (25.22)    52 (27.66)    137 (26.10)                     0.54
  Men                                                  252 (74.78)   136 (72.34)   388 (73.90)  
  Smoking status                                                                                
  No                                                   225 (66.77)   108 (57.45)   333 (63.43)    0.03[\*](#nt101){ref-type="table-fn"}
  Yes                                                  112 (33.23)   80 (42.55)    192 (36.57)  
  Alcohol intake                                                                                
  No                                                   201 (59.64)   120 (63.83)   321 (61.14)                     0.35
  Yes                                                  136 (40.36)   68 (36.17)    204 (38.86)  
  Hepatitis B virus[a](#nt102){ref-type="table-fn"}                                             
  Negative                                             223 (86.77)   108 (57.45)   331 (74.38)   \<0.001[\*](#nt101){ref-type="table-fn"}
  Positive                                             34 (13.23)    80 (42.55)    114 (25.62)  

\**p*\<0.05 considered statistically significant.

80 frequency missing data in control group.

MiRNA Gene Polymorphisms {#s3b}
------------------------

The distribution of miRNA gene polymorphisms is described in [Table 2](#pone-0089930-t002){ref-type="table"}. In our recruited control group, the frequencies of miRNA146a rs2910164 (χ^2^ value: 1.92), miRNA196 rs11614913 (χ^2^ value: 0.0005), and miRNA499 rs3746444 (χ^2^ value: 0.98) were in Hardy-Weinberg equilibrium, respectively, except for miRNA149 rs2292832 (χ^2^ value: 59.86). By using a multiple logistic regression model to estimate the adjusted odds ratio (AOR), we observed a significantly higher risk for people who carried the CT (AOR = 2.52, 95% confidence interval \[CI\] = 1.63--3.86) or CC (AOR = 20.7, 95% CI = 2.60--165.90) genotypes of miRNA499 (rs3746444). Because of the insufficient size of the CC group, the CT and CC genotype samples were combined, producing similar results (AOR = 2.84, 95% CI = 1.88--4.30). In addition, no statistical significance was observed in the other 3 gene polymorphisms (rs2910164, rs2292832, and rs11614913). Similarly, a significantly higher risk for people who carried the CT (AOR = 6.14, 95% confidence interval \[CI\] = 1.32--28.56) or CC (AOR = 4.75, 95% CI = 1.32--17.01) genotypes of miRNA499 (rs3746444) was observed in the HBV-infection group (Table S1 in [File S1](#pone.0089930.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0089930.t002

###### Distribution of miRNAs genotypes in healthy controls and hepatocellular carcinoma patients.

![](pone.0089930.t002){#pone-0089930-t002-2}

  Gene                     Control        Case                                      OR                                                  AOR[a](#nt103){ref-type="table-fn"}
  --------------------- ------------- ------------- ------------------------------------------------------------------- -------------------------------------------------------------------
  miRNA146ars2910164                                                                                                    
  CC                     141 (41.84)   84 (44.68)                                Reference                                                           Reference
  CG                     146 (43.32)   82 (43.62)                     0.94 (0.64--1.38, *p* = 0.763)                                      0.93 (0.63--1.37, *p* = 0.714)
  GG                     50 (14.84)    22 (11.70)                     0.74 (0.42--1.31, *p* = 0.297)                                      0.72 (0.40--1.27, *p* = 0.253)
  CG/GG                  196 (58.16)   104 (55.32)                    0.89 (0.62--1.28, *p* = 0.528)                                      0.83 (0.59--1.18, *p* = 0.300)
  miRNA149 rs2292832                                                                                                    
  TT                     246 (73.00)   139 (73.94)                               Reference                                                           Reference
  CT                     64 (18.99)    36 (19.15)                     0.99 (0.63--1.57, *p* = 0.984)                                      0.99 (0.62--1.58, *p* = 0.982)
  CC                      27 (8.01)     13 (6.91)                     0.85 (0.43--1.71, *p* = 0.651)                                      0.82 (0.41--1.66, *p* = 0.579)
  CT/CC                  91 (27.00)    49 (26.06)                     0.95 (0.64--1.43, *p* = 0.816)                                      0.94 (0.63--1.41, *p* = 0.767)
  miRNA196 rs11614913                                                                                                   
  TT                     100 (29.67)   66 (35.11)                                Reference                                                           Reference
  CT                     167 (49.55)   81 (43.09)                     0.74 (0.49--1.11, *p* = 0.140)                                      0.70 (0.46--1.06, *p* = 0.090)
  CC                     70 (20.77)    41 (21.81)                     0.89 (0.54--1.46, *p* = 0.637)                                      0.93 (0.56--1.54, *p* = 0.785)
  CT/CC                  237 (70.33)   122 (64.89)                    0.78 (0.53--1.14, *p* = 0.200)                                      0.90 (0.64--1.26, *p* = 0.544)
  miRNA499 rs3746444                                                                                                    
  TT                     281 (83.38)   119 (63.30)                               Reference                                                           Reference
  CT                     55 (16.32)    60 (31.91)     2.58 (1.69--3.94, *p*\<0.001)[\*](#nt104){ref-type="table-fn"}      2.48 (1.62--3.81, *p*\<0.001)[\*](#nt104){ref-type="table-fn"}
  CC                      1 (0.30)      9 (4.79)     21.2 (2.66--169.55, *p* = 0.004)[\*](#nt104){ref-type="table-fn"}   22.1 (2.73--178.40, *p* = 0.003)[\*](#nt104){ref-type="table-fn"}
  CT/CC                  56 (16.62)    69 (36.70)     2.91 (1.93--4.40, *p*\<0.001)[\*](#nt104){ref-type="table-fn"}      2.91 (1.93--4.42, *p*\<0.001)[\*](#nt104){ref-type="table-fn"}

AOR adjusted age, sex, smoking status and drinking status.

\**p* value \<0.05.

Gene Polymorphisms with Clinicopathologic TNM Staging {#s3c}
-----------------------------------------------------

The distribution of clinical status and miRNA polymorphisms in HCC patients were estimated to clarify the role of miRNA polymorphisms in the clinicopathologic state of HCC patients. No significant association was found between the levels of these HCC clinical pathological markers as well as presence of HBV or HCV, liver cirrhosis and genotypes for any of the RNA SNPs in HCC patients ([Table 3](#pone-0089930-t003){ref-type="table"} and [Table 4](#pone-0089930-t004){ref-type="table"}). However, the trend of TC+CC genotype of miRNA rs2292832 for distant metastasis risk was higher in the male participants (Table S2 in [File S1](#pone.0089930.s001){ref-type="supplementary-material"}) while that of female participants was not (Table S3 in [File S1](#pone.0089930.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0089930.t003

###### Relationship of clinical TNM stages and miRNAs genotypes in liver cancer patients.

![](pone.0089930.t003){#pone-0089930-t003-3}

  Variables                rs2910164     rs2292832                 rs11614913                  rs3746444                                                                                                                                                      
  ----------------------- ------------ ------------- --------------------------------------- ------------- ------------ --------------------------------------- ------------ ------------- --------------------------------------- ------------- ------------ ---------------------------------------
  Clinical stage                                                                                                                                                                                                                                              
  Stage I/II               49 (58.33)   66 (63.46)                    0.471                   85 (61.15)    30 (61.22)                   0.992                   40 (60.61)   75 (61.48)                    0.911                   73 (61.34)    42 (60.87)                   0.947
  Stage III/IV             35 (41.67)   38 (36.54)                                            54 (38.85)    19 (38.78)                                           26 (39.39)   47 (38.52)                                            46 (38.66)    27 (39.13)  
  Tumor size                                                                                                                                                                                                                                                  
  T1+ T2                   50 (59.52)   67 (64.42)                    0.496                   88 (63.31)    29 (59.18)                   0.615                   39 (59.09)   78 (63.93)                    0.510                   75 (63.03)    42 (60.87)                   0.775
  T3+ T4                   34 (40.48)   37 (35.58)                                            51 (36.69)    20 (40.82)                                           27 (40.91)   44 (36.07)                                            44 (36.97)    27 (39.13)  
  Lymph node metastasis                                                                                                                                                                                                                                       
  Negative                 79 (94.05)   100 (96.15)   0.514[a](#nt105){ref-type="table-fn"}   131 (94.24)   48 (97.96)   0.294[a](#nt105){ref-type="table-fn"}   62 (93.94)   117 (95.90)   0.554[a](#nt105){ref-type="table-fn"}   112 (94.12)   67 (97.10)   0.353[a](#nt105){ref-type="table-fn"}
  Positive                  5 (5.95)     4 (3.85)                                              8 (5.76)      1 (2.04)                                             4 (6.06)     5 (4.10)                                              7 (5.88)      2 (2.90)   
  Distant metastasis                                                                                                                                                                                                                                          
  Negative                 78 (92.86)   99 (95.19)                    0.493                   133 (95.68)   44 (89.80)                   0.136                   62 (93.94)   115 (94.26)   0.922[a](#nt105){ref-type="table-fn"}   110 (92.44)   67 (97.10)   0.194[a](#nt105){ref-type="table-fn"}
  Positive                  6 (7.14)     5 (4.81)                                              6 (4.32)     5 (10.20)                                             4 (6.06)     7 (5.74)                                              9 (7.56)      2 (2.90)   

Use Fisher's exact test.

10.1371/journal.pone.0089930.t004

###### Relationship of clinical statuses and miRNAs genotypes in liver cancer patients.

![](pone.0089930.t004){#pone-0089930-t004-4}

  Variables           rs2910164    rs2292832    rs11614913    rs3746444                                                                                    
  ------------------ ------------ ------------ ------------ ------------- ------------ ------- ------------ ------------ ------- ------------ ------------ -------
  HBsAg                                                                                                                                                    
  Negative            52 (61.90)   57 (54.81)     0.322      82 (58.99)    27 (55.10)   0.633   33 (50.00)   76 (62.30)   0.102   66 (55.46)   43 (62.32)   0.357
  Positive            32 (38.10)   47 (45.19)                57 (41.01)    22 (44.90)           33 (50.00)   46 (37.70)           53 (44.54)   26 (37.68)  
  Anti-HCV                                                                                                                                                 
  Negative            44 (52.38)   53 (50.96)     0.841      69 (49.64)    28 (57.14)   0.367   34 (51.52)   63 (51.64)   0.983   67 (56.30)   30 (43.48)   0.079
  Positive            40 (47.62)   51 (49.04)                70 (50.36)    21 (42.86)           32 (48.48)   59 (48.36)           52 (43.70)   39 (56.52)  
  Child-Pugh grade                                                                                                                                         
  A                   62 (73.81)   75 (72.12)     0.796      103 (74.10)   34 (69.39)   0.526   46 (69.70)   91 (74.59)   0.475   85 (71.43)   52 (75.36)   0.551
  B or C              22 (26.19)   29 (27.88)                36 (25.90)    15 (30.61)           20 (30.30)   31 (25.41)           34 (28.57)   17 (24.64)  
  Liver Cirrhosis                                                                                                                                          
  Negative            21 (25.00)   29 (27.88)     0.654      41 (29.50)    9 (18.37)    0.129   13 (19.70)   37 (30.33)   0.113   30 (25.21)   20 (28.99)   0.572
  Positive            63 (75.00)   75 (72.12)                98 (70.50)    40 (81.63)           53 (80.30)   85 (69.67)           89 (74.79)   49 (71.01)  

Use Fisher's exact test.

Gene Polymorphisms with Laboratory Status {#s3d}
-----------------------------------------

We associated laboratory status with gene polymorphisms, including α-fetoprotein (ng/mL), AST (IU/L), ALT (IU/L), and AST/ALT ratios, as shown in [Table 5](#pone-0089930-t005){ref-type="table"}. We observed a significantly lower ratio in the patients who carried rs2910164 CG or GG genotypes (*p* = 0.003).

10.1371/journal.pone.0089930.t005

###### Relationship of HCC laboratory status and miRNAs genotypes in liver cancer patients.

![](pone.0089930.t005){#pone-0089930-t005-5}

  Variables              α-Fetoprotein        AST             ALT                       AST/ALT
  --------------------- --------------- --------------- --------------- ----------------------------------------
  miRNA146a rs2910164                                                   
  CC                     4211.1±18853    192.93±363.25   122.52±171.11                 1.73±1.44
  CG/GG                  4459.9±16050    196.55±389.84   196.84±362.98                 1.25±0.70
  *p* value                  0.922           0.948           0.086       0.003[\*](#nt107){ref-type="table-fn"}
  miRNA149 rs2292832                                                    
  TT                     3584.9±16267    198.77±401.56   170.74±320.38                 1.42±1.04
  CT/CC                  6515.6±20006    184.02±300.92   143.48±207.47                 1.59±1.33
  *p* value                  0.309           0.815           0.579                       0.359
  miRNA196 rs11614913                                                   
  TT                     3599.4±14256    199.35±416.04   173.52±332.77                 1.42±0.74
  CT/CC                  4754.1±18801    192.54±356.22   158.29±273.48                 1.49±1.29
  *p* value                  0.664           0.906           0.736                       0.705
  miRNA499 rs3746444                                                    
  TT                     2871.7±11986    214.91±434,71   167.92±333.43                 1.54±1.24
  CT/CC                  6896.2±23757    160.48±247.88   156.25±214.63                 1.34±0.87
  *p* value                  0.125           0.342           0.794                       0.254

*\*p* value \<0.05.

Gene Polymorphism with Environmental Risk Factors {#s3e}
-------------------------------------------------

Furthermore, we considered the environmental risk factors of hepatocellular carcinoma such as smoking and alcohol consumption. The risk factors were then combined with miRNA gene polymorphisms and examined to determine whether interactions existed between the 2 factors. The relationship between genotype and smoking status indicated that people who carried rs3746444 CT or CC genotypes and non-smoking habits had an increased odds ratio (OR = 2.34, 95% CI = 1.36--4.00), and those with CT or CC genotypes and smoking habits had the highest odds ratio (OR = 4.69, 95% CI = 2.52--8.70) ([Table 6](#pone-0089930-t006){ref-type="table"}). The result for patients who carried the re3746444 CT or CC genotypes was similar to that observed for patients who consumed alcohol (AOR = 3.44, 95% CI = 1.69--7.00) ([Table 7](#pone-0089930-t007){ref-type="table"}).

10.1371/journal.pone.0089930.t006

###### Association of miRNA genotype and smoking status.

![](pone.0089930.t006){#pone-0089930-t006-6}

  Variable                                                 Control                                     Case                                     OR                                                AOR[a](#nt108){ref-type="table-fn"}
  ------------------------- ---------------------------------------------------------------------- ------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  miRNA146a rs2910164                                                                                                                                                              
  CC and non-smoker                                       94 (27.89)                                50 (26.60)                               Reference                                                         Reference
  CG or GG and non-smoker                                131 (38.87)                                58 (30.85)                     0.83 (0.53--1.32, *p* = 0.436                                    0.80 (0.50--1.31, *p* = 0.376)
  CC and smoker                                           47 (13.95)                                34 (18.09)                    1.36 (0.78--2.38, *p* = 0.280)                                    1.37 (0.78--2.47, *p* = 0.293)
  CG or GG and smoker                                     65 (19.29)                                46 (24.47)                    1.33 (0.80--2.22, *p* = 0.273)                                    1.36 (0.78--2.36, *p* = 0.278)
  Test for interaction                        ?^2^ = 5.102 (3 d.f.), *p* = 0.164                                                                                                   
  miRNA149 rs2292832                                                                                                                                                               
  TT and non-smoker                                      164 (48.66)                                50 (43.09)                               Reference                                                         Reference
  CT or CC and non-smoker                                 61 (18.10)                                27 (14.36)                    0.90 (0.53--1.52, *p* = 0.682)                                    0.85 (0.49--1.47, *p* = 0.550)
  CT or CC and smoker                                     82 (24.33)                                58 (30.85)                    1.43 (0.93--2.20, *p* = 0.101)                    1.66 (1.05--2.64, *p* = 0.003)[\*](#nt109){ref-type="table-fn"}
  CT or CC and smoker                                     30 (8.90)                                 114 (11.70)                   1.49 (0.81--2.74, *p* = 0.205)                                    1.88 (0.99--3.59, *p* = 0.054)
  Test for interaction                       ?^2^ = 4.689 (3 d.f.), *p = *0.1960                                                                                                   
  miRNA196 rs11614913                                                                                                                                                              
  TT and non-smoker                                       74 (21.96)                                34 (18.09)                               Reference                                                         Reference
  CT or CC and non-smoker                                151 (44.81)                                74 (39.36)                    1.07 (0.65--1.75, *p* = 0.797)                                    0.99 (0.59--1.66, *p* = 0.962)
  CT or CC and smoker                                     26 (7.72)                                 32 (17.02)    2.68 (1.39--5.17, *p* = 0.003)[\*](#nt109){ref-type="table-fn"}   2.69 (1.34--5.41, *p* = 0.005)[\*](#nt109){ref-type="table-fn"}
  CT or CC and smoker                                     86 (25.52)                                48 (25.53)                    1.22 (0.71--2.08, *p* = 0.479)                                    1.21 (0.68--2.13, *p* = 0.516)
  Test for interaction       ?^2^ = 11.175 (3 d.f.), *p* = 0.010[\*](#nt109){ref-type="table-fn"}                                                                                  
  miRNA499 rs3746444                                                                                                                                                               
  TT and non-smoker                                      188 (55.79)                                74 (39.36)                               Reference                                                         Reference
  CT or CC and non-smoker                                 37 (10.98)                                34 (18.09)    2.34 (1.36--4.00, *p* = 0.002)[\*](#nt109){ref-type="table-fn"}   2.41 (1.36--4.26, *p* = 0.002)[\*](#nt109){ref-type="table-fn"}
  CT or CC and smoker                                     93 (27.60)                                45 (23.94)                    1.23 (0.79--1.92, *p* = 0.364)                                    1.37 (0.85--2.20, *p* = 0.192)
  CT or CC and smoker                                     19 (5.64)                                 35 (18.62)    4.69 (2.52--8.70, *p*\<0.001)[\*](#nt109){ref-type="table-fn"}    5.64 (2.87--11.06, *p*\<0.001)[\*](#nt109){ref-type="table-fn"}
  Test for interaction       ?^2^ = 31.409 (3 d.f.), *p*\<0.001[\*](#nt109){ref-type="table-fn"}                                                                                   

AOR adjusted age, gender and alcohol intake.

\**p* value \<0.05.

10.1371/journal.pone.0089930.t007

###### Association of miRNA genotype and alcohol intake status.

![](pone.0089930.t007){#pone-0089930-t007-7}

  Variable                                                        Control                                    Case                                    OR                                                AOR[a](#nt110){ref-type="table-fn"}
  --------------------------------- -------------------------------------------------------------------- ------------ ----------------------------------------------------------------- -----------------------------------------------------------------
  miRNA146a rs2910164                                                                                                                                                                   
  CC and non-alcohol intake                                      88 (26.11)                               53 (28.19)                              Reference                                                         Reference
  CG or GG and non-alcohol intake                               113 (33.53)                               67 (35.64)                   0.98 (0.62--1.55, *p* = 0.946)                                    0.94 (0.59--1.49, *p* = 0.792)
  CG or GG and consumer                                          53 (15.73)                               31 (16.49)                   0.97 (0.56--1.70, *p* = 0.918)                                    0.87 (0.48--1.57, *p* = 0.651)
  CG or GG and alcohol intake                                    83 (24.63)                               37 (19.68)                   0.74 (0.44--1.24, *p* = 0.253)                                    0.64 (0.37--1.10, *p* = 0.110)
  Test for interaction                               ?^2^ = 1.687 (3 d.f.) *p* = 0.640                                                                                                  
  miRNA149 rs2292832                                                                                                                                                                    
  TT and non-alcohol intake                                     140 (41.54)                               91 (48.40)                              Reference                                                         Reference
  CT or CC and non-alcohol intake                                61 (18.10)                               29 (15.43)                   0.73 (0.44--1.22, *p* = 0.234)                                    0.74 (0.44--1.26, *p* = 0.269)
  CT or CC and consumer                                         106 (31.45)                               48 (25.53)                   0.70 (0.45--1.07, *p* = 0.100)                                    0.61 (0.38--0.97, *p* = 0.036)
  CT or CC and alcohol intake                                    30 (8.90)                                20 (10.64)                   1.03 (0.55--1.92, *p* = 0.937)                                    0.98 (0.51--1.89, *p* = 0.955)
  Test for interaction                               ?^2^ = 3.620 (3 d.f.) *p* = 0.306                                                                                                  
  miRNA196 rs11614913                                                                                                                                                                   
  TT and non-alcohol intake                                      64 (18.99)                               38 (20.21)                              Reference                                                         Reference
  CT or CC and non-alcohol intake                               137 (40.65)                               82 (43.62)                   1.01 (0.62--1.64, *p* = 0.974)                                    0.95 (0.58--1.57, *p* = 0.854)
  CT or CC and consumer                                          36 (10.68)                               28 (14.89)                   1.31 (0.69--2.48, *p* = 0.406)                                    1.05 (0.53--2.10, *p* = 0.884)
  CT or CC and alcohol intake                                   100 (29.67)                               40 (21.28)                   0.67 (0.39--1.16, *p* = 0.154)                    0.53 (0.29--0.96, *p* = 0.036)[\*](#nt111){ref-type="table-fn"}
  Test for interaction                               ?^2^ = 5.293 (3 d.f.) *p* = 0.152                                                                                                  
  miRNA499 rs3746444                                                                                                                                                                    
  TT and non-alcohol intake                                     163 (48.37)                               78 (41.49)                              Reference                                                         Reference
  CT or CC and non-alcohol intake                                38 (11.28)                               42 (22.34)   2.31 (1.38--3.87, *p* = 0.001)[\*](#nt111){ref-type="table-fn"}   2.43 (1.43--4.12, *p* = 0.001)[\*](#nt111){ref-type="table-fn"}
  CT or CC and consumer                                         118 (35.01)                               41 (21.81)                   0.73 (0.47--1.13, *p* = 0.160)                                    0.66 (0.41--1.06, *p* = 0.085)
  CT or CC and alcohol intake                                    18 (5.34)                                27 (14.36)   3.14 (1.63--6.03, *p*\<0.001)[\*](#nt111){ref-type="table-fn"}    3.44 (1.69--7.00, *p*\<0.001)[\*](#nt111){ref-type="table-fn"}
  Test for interaction               ?^2^ = 29.345 (3 d.f.) *p*\<0.001[\*](#nt111){ref-type="table-fn"}                                                                                 

AOR adjusted age, gender and smoking status.

\**p* value \<0.05.

Discussion {#s4}
==========

The results of this investigation indicate that miRNA499 rs3746444 is highly associated with hepatocellular carcinoma. Regarding genotype distribution and environmental risk factors, such as smoking and alcohol consumption, miRNA499 plays a crucial role in hepatocellular carcinoma.

MiRNA499 rs3746444 has been discussed in relation to numerous cancers. A meta-analysis of 7188 patients with several cancers compared with 8548 control participants reported that a significant association exists between miR499 rs3746444 polymorphisms and an increased risk of cancer [@pone.0089930-Wang2], [@pone.0089930-Wang3]. MiRNA499 rs3746444 has been reported to increase susceptibility to hepatocellular carcinoma in the Chinese population [@pone.0089930-Xiang1]. The results obtained after increasing the sample size were similar. Several studies of Asian populations have reported the same finding; that is, miRNA499 is associated with cancer [@pone.0089930-Qiu1], [@pone.0089930-Chen1]. However, in Caucasian population, miRNA499 has not been associated with cancer [@pone.0089930-Wang4]. Our findings may through the racial difference and it's specifically direct against to Asians. Furthermore, the basic laboratory study also demonstrated that miRNA499 may bind to and reduce the expression of c-MET mRNA, which promotes cell apoptosis and inhibits cell proliferation [@pone.0089930-Buurman1].

Previous studies have shown that miRNA146 can be used as a biomarker and therapeutic target for peripartum cardiomyopathy [@pone.0089930-Halkein1], and may negatively regulate the activity of bone marrow stem cells [@pone.0089930-Matysiak1]. Other studies have linked miRNA146 to inflammatory immune system responses or T-cell activity [@pone.0089930-Ichii1], [@pone.0089930-Yang1]. Compared to the laboratory status, we observed a significant difference in the AST/ALT ratio of patients who carried CG or GG genotypes compared with those who carried the CC genotype, which may related to the liver damage caused by alcohol. Further, serum liver enzymes were associated with long-term mortality, especially the populations with low ALT and AST levels [@pone.0089930-Koehler1].

A slight difference exists in distant tumor metastasis caused by miRNA149 rs2292832 gene polymorphisms (Table S2 in [File S1](#pone.0089930.s001){ref-type="supplementary-material"}). Recent studies have shown that miRNA149 gene polymorphisms are associated with the prognosis for patients diagnosed with head and neck carcinoma [@pone.0089930-Tu1]. Øster et al., also found that miRNA149 can regulate SPRX2 expression and CpG promotes hypomethylation in colorectal cancer [@pone.0089930-ster1]. Several in vivo studies have associated miRNA149 with the p53 gene and reported that miRNA149 may serve as an oncogenic regulator of p53 expression [@pone.0089930-Jin1]. We observed a slight difference in distant tumor metastasis caused by miRNA149; however, a larger sample size and additional laboratory experiments are required to verify this finding.

In this study, miRNA196 exhibited a slight association with hepatocellular carcinoma after patients' alcohol consumption was considered. However, the test results for an interaction between gene polymorphisms and cancer risk factors were not statistically significant (*p = *0.152). Previous studies have shown that miRNA196 is associated with transcription factors and affects cancer development and progression [@pone.0089930-Li2], [@pone.0089930-Chen2]. In addition, increased miRNA196 expression improves the survival and prognosis for patients diagnosed with leukemia [@pone.0089930-Popovic1]. Nonetheless, the results obtained in this research do not provide sufficient evidence of a relationship between miR196 and hepatocellular carcinoma. Furthermore, after considering environmental risk factors, such as smoking and alcohol consumption, we combined the gene polymorphisms and analysis results of the interactions caused by the 2 risk factors. Considered with the viral factors, carried miR34b/c rs4938723 CC was significantly associated with HCC. And with miR196a rs11614913 was not associated with HCC, but carried CC genotype significantly enhanced the influences caused by rs4938723 in women population [@pone.0089930-Han1]. For patients in the smoking and alcohol consumption groups, mirRNA499 can cause interactions (*p*\<0.001) and increase the OR for developing hepatocellular carcinoma. This may be because the various functions of miRNAs not only influence tumor differentiation and proliferation, but also promote inflammation and apoptosis.

Sample size was the greatest limitation in our study. The sample comprised a fewer number of female participants than male participants, which may be due to differences in lifestyle factors, such as smoking status and alcohol consumption. Substantial exposure to the environmental risk factors can easily result in underestimation of gene affections in subsequent analyses. We used a regression model to reduce the effect of potential confounding factors, but estimating the genetic effects under environmental affections remained difficult.

In conclusion, we observed a strong relationship between miRNA499 gene polymorphisms and hepatocellular carcinoma. People who carry miRNA499 rs3746444 CT or CC genotypes may have a high susceptibility to hepatocellular carcinoma. In addition, we observed a strong interaction and increased odds ratio for hepatocellular carcinoma development between miRNA499 gene polymorphisms and smoking and alcohol consumption. Although we observed evidence that miRNA499 rs3746444 is related to hepatocellular carcinoma susceptibility, additional laboratory experiments and functional assays are required to confirm the effects of miRNA499 rs3746444 gene polymorphisms on hepatocellular carcinoma.
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